Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
Jeffrey S HealeyRenato D LopesChristopher B GrangerMarco AlingsLena RivardWilliam F McIntyreDan AtarDavid H BirnieGiuseppe BorianiA John CammDavid ConenJulia W ErathMichael R GoldStefan H HohnloserJohn IpJosef KautznerValentina KutyifaCecilia LindePhilippe MaboGeorges MairesseJuan Benezet MazuecosJens Cosedis NielsenFrancois PhilipponMarco ProiettiChristian SticherlingJorge A WongDavid J WrightIgnatius G ZarragaShelagh B CouttsAndrew KaplanMarta PomboFelix Ayala-ParedesLizhen XuKim SimekSandra NevillsRajibul MianStuart J Connollynull nullPublished in: The New England journal of medicine (2023)
Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).